ArticleNeuropsychiatric disease and treatment2017
The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease.
Article in Neuropsychiatric disease and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Causal relationships between neuropsychiatric disorders and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study.BMC gastroenterology · 2024Pooled it
- Prevalence and Associated Factors of Metabolic Dysfunction-Associated Steatotic Liver Disease Across Obesity Metabolic Phenotypes in Chronic Schizophrenia.International journal of general medicine · 2026Article
- Effect of Antidepressants on Non-alcoholic Fatty Liver Disease and their Underlying Mechanism.Current medicinal chemistry · 2025Article
- Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease (NAFLD) in Non-Obese Patients with Schizophrenia: A Retrospective Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Prevalence and Influence Factors for Non-Alcoholic Fatty Liver Disease in Long-Term Hospitalized Patients with Schizophrenia: A Cross-Sectional Retrospective Study.Neuropsychiatric disease and treatment · 2023Article
- Gastrointestinal and liver disease in patients with schizophrenia: A narrative review.World journal of gastroenterology · 2022Review
- Behavioral health disorders related to nonalcoholic steatohepatitis.Clinical liver disease · 2022Review
- Management of Psychiatric Disorders in Patients with Hepatic and Gastrointestinal Diseases.Indian journal of psychiatry · 2022Article
- Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China.BMC gastroenterology · 2021Article
- Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools.Hepatology international · 2021Article
- Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study.Hepatology international · 2021Observational
- Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.BMC medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn this study, we compared the prevalence rate of non-alcoholic fatty liver disease (NAFLD) between young males with schizophrenia and the general young males as the control group, and we also investigated the risk factors of NAFLD in young males with schizophrenia. MATERIALS AND
methodsThis is a large cross-sectional study consisting of the study group and parallel control group. The study group comprises 202 cases of young males with schizophrenia recruited from Liaoning province Demobilized Soldiers Kangning Hospital, and 149 healthy young males were recruited as the control group. The clinical evaluation included Positive and Negative Syndrome Scale (PANSS), basic information, disease-related information, and physical examination information. The laboratory tests included fasting blood glucose, total cholesterol, triglyceride, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). The physical examination included liver ultrasonography.
resultsNo statistical difference was observed between the study and control groups regarding age (30.5±3.9 vs 30.7±3.6), body mass index (BMI), blood pressure, fasting glucose level, and total cholesterol. NAFLD was observed in both the study and control groups. The prevalence of NAFLD was 49.5% (100/202) in the study group, and 20.1% (30/149) in the control group. The study group was further divided into NAFLD group and non-NAFLD group. There were significant differences in medication combination, drug dosage, negative factor score in PANSS (14.1±4.0 vs 12.7±4.5), BMI, fasting glucose level, total cholesterol, triglyceride, ALT, and AST between NAFLD group and non-NAFLD group. According to the results of the multiple-factor analysis, the onset of NAFLD among young males with schizophrenia was significantly correlated with the following factors: triglyceride, BMI, medication combination, drug dosage, and negative factor score in PANSS.
conclusionThe prevalence of NAFLD in the study group was significantly higher than that in the control group. Multivariate analysis indicated that, triglyceride, BMI, medication combination, drug dosage, and negative factor score in PANSS were significantly related to NAFLD in patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.